Cue Biopharma, Inc.
CUEAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 1, 2026 | B.Riley Financial | Mayank Mamtani | $83.00(+221%) | $25.87 | StreetInsider |
| Nov 15, 2024 | Jefferies | Maury Raycroft | $4.00(+211%) | $1.28 | StreetInsider |
| Jul 26, 2024 | JMP Securities | Reni Benjamin | $2.00(+184%) | $0.70 | TheFly |
| Mar 13, 2024 | Jefferies | Maury Raycroft | $6.00(+179%) | $2.15 | StreetInsider |
| Nov 20, 2022 | Piper Sandler | Edward Tenthoff | $7.00(+117%) | $3.22 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citizens Capital Markets | maintain | Market Outperform | Apr 2, 2025 |
| Stifel | maintain | Buy | Aug 20, 2024 |
| Piper Sandler | maintain | Overweight | Jul 26, 2024 |
| JMP Securities | maintain | Market Outperform | Jul 26, 2024 |
| Oppenheimer | maintain | Outperform | Apr 9, 2024 |
| Stifel | maintain | Buy | Apr 9, 2024 |
| Piper Sandler | maintain | Overweight | Apr 3, 2024 |
| Piper Sandler | maintain | Overweight | Nov 6, 2023 |
| Stifel | maintain | Buy | Jun 15, 2023 |
| JMP Securities | maintain | Outperform | May 15, 2023 |
| Stifel | maintain | Buy | Mar 22, 2023 |
| Oppenheimer | maintain | Outperform | Mar 22, 2023 |
| Piper Sandler | maintain | Overweight | Nov 21, 2022 |
| Oppenheimer | maintain | Outperform | Aug 24, 2022 |
| Oppenheimer | maintain | Outperform | Mar 21, 2022 |
| Craig-Hallum | maintain | Buy | Mar 18, 2022 |
| Berenberg | maintain | Buy | Nov 24, 2020 |
| Stifel | maintain | Buy | May 20, 2020 |
| Oppenheimer | maintain | Outperform | May 20, 2020 |
| Stifel | maintain | Buy | Apr 21, 2020 |
| Stifel | maintain | Buy | Apr 9, 2020 |
| JMP Securities | maintain | Outperform | Mar 6, 2020 |
| Oppenheimer | maintain | Outperform | Feb 25, 2020 |
| BTIG | maintain | Buy | Jan 28, 2020 |
| JMP Securities | maintain | Market Outperform →Outperform | Jan 22, 2020 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-2.24| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-24.14 | $-1.69 | $7.9M | $3.0M |
| May 14, 2026 | $-1.08 | $-3.30 | $5.7M | $2.5M |
| Mar 16, 2026 | $0.30 | $-2.70 | $21.9M | $1.0M |
| Nov 12, 2025 | $-2.10 | $-2.80 | $2.1M | $2.3M |
| Aug 12, 2025 | $-2.70 | $-3.90 | $3.0M | $2.0M |
| May 12, 2025 | $-5.11 | $-4.20 | $421.0K | $1.3M |
| Mar 31, 2025 | $-3.90 | $-2.58 | $1.6M | $1.7M |
| Nov 14, 2024 | $-5.11 | $-5.47 | $3.3M | $1.5M |
News
Cue Biopharma NASDAQ: CUE reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines.
Cue Biopharma (NASDAQ: CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluated subcutaneous CUE-221 at doses of 1 mg/kg, 2 mg/kg and 4 mg/kg, administered every four weeks. The trial
I am initiating Cue Biopharma with a "Buy" rating, driven by positive phase 2 results for CUE-221 in chronic spontaneous urticaria [CSU]. CUE-221's novel dual mechanism of action demonstrated superior efficacy to XOLAIR, with 54% of patients achieving complete hive resolution at 12 weeks [p < 0.005]. Upcoming catalysts include 36-week PK and IgE data in 2026, and planned phase 2b/3 global studies in CSU and food allergy, targeting large market opportunities.
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript
Cue Biopharma (NASDAQ:CUE) on Sunday shared topline results from a Phase 2 trial of CUE-221 in patients with moderate to severe chronic spontaneous urticaria.
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cue Biopharma, Inc. (NASDAQ: CUE) on behalf of the company's shareholders. The investigation seeks to determine whether Cue Biopharma's directors breached their fiduciary duties in connection with recent corporate actions.
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.